Lindis Biotech, Gmbh V. Amgen Inc.

Case Background

Lindis Biotech, GmbH filed a patent infringement lawsuit against Amgen Inc. for the willful infringement of its patented immunotherapy regimen for cancer treatment. The case was filed in the United States District Court, Delaware (Wilmington). Judge Gregory B. Williams presided over this case. [Case number: 1:22cv35]

Cause

Lindis Biotech, GmbH ("Lindis") developed a patented immunotherapy regimen to address major challenges in cancer treatment. This innovative approach uses bispecific antibodies to target cancer cells, minimize harm to healthy tissue, and prevent excessive immune responses. Unlike traditional therapies like chemotherapy and radiation, which often damage healthy cells and suppress immunity, Lindis’s regimen offers a safer and more effective alternative. Dr. Horst Lindhofer and Dr. Marcus M. Heiss, the inventors behind Lindis’s patents, devised a groundbreaking method to enhance immunotherapy. Their regimen pairs glucocorticoids with bispecific antibodies. Administering glucocorticoids before antibodies reduces the risk of cytokine storms—dangerous immune reactions—while preserving the antibodies’ cancer-fighting properties. This method allows higher antibody doses without compromising safety. Lindis holds U.S. and European patents, including U.S. Patent Nos. 8,709,421 and 10,071,158, for its regimen. These patents cover the use of bispecific antibodies targeting CD19 (a